European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- __full__ -
: Tablets designed to disperse rapidly in the mouth or dissolve in water before administration. 3. Production and Quality Control Requirements
| Average mass (mg) | Percentage deviation | |-------------------|----------------------| | ≤ 80 | 10% | | 81 – 250 | 7.5% | | > 250 | 5% |
The monograph requires a visual description of the tablets (color, shape, markings). More critically, it mandates a specific identification test for the active substance(s), typically using High-Performance Liquid Chromatography (HPLC) or Infrared (IR) spectroscopy. This prevents mix-ups and ensures the correct drug is present.
These have separate monographs (e.g., 2066, 2067, etc.). European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
Failing to adhere to the 2023 revisions of 0478 is a in any EMA inspection, leading to potential import bans, product recalls, or manufacturing authorization suspension.
Ph. Eur. Monograph 0478 provides a robust framework for ensuring the quality, safety, and efficacy of tablet formulations. By defining strict standards for identity, content uniformity, disintegration, and dissolution, the monograph ensures that patients receive a consistent dose of medication that performs reliably in the body. It remains a dynamic document, updated periodically to reflect advances in pharmaceutical technology and analytical science.
: Uncoated tablets containing acid substances and carbonates/hydrogen carbonates. They react rapidly in water to release carbon dioxide, dissolving or dispersing the drug for consumption. : Tablets designed to disperse rapidly in the
(disintegrating in the mouth within 3 minutes). Key Quality Control Requirements
Understanding how to apply the monograph in practice is crucial for manufacturers.
| Requirement | Details | | :--- | :--- | | | Tablets must be robust enough for handling and subsequent processing. This is assessed through tests like Friability of uncoated tablets (2.9.7) and Resistance to crushing of tablets (2.9.8) . | | Uniformity of Subdivided Parts (for Scored Tablets) | For tablets with break-marks used to split doses, the manufacturer must demonstrate that the subdivided parts are uniform. The test involves breaking 30 tablets, weighing one half from each, and ensuring no more than one mass falls outside 85-115% of the average mass. | | Microbiological Quality | Suitable measures must be taken to ensure microbiological quality throughout the lifecycle, in line with general chapter 5.1.4. | More critically, it mandates a specific identification test
May take up to 60 minutes depending on the coating type.
In the landscape of global pharmaceutical regulation, quality standards serve as the silent guardians of public health. Among the most authoritative of these standards is the European Pharmacopoeia (Ph. Eur.), a legally binding benchmark for all medicines marketed within European Union member states. Within this collection, , occupies a foundational role. Unlike monographs for specific active substances (e.g., Paracetamol or Atorvastatin), the Tablets monograph establishes the general quality requirements for one of the most common and ancient pharmaceutical dosage forms. This essay examines the scope, key tests, and regulatory significance of Ph. Eur. Monograph 0478, arguing that it provides a universal quality framework that ensures the safety, efficacy, and reliability of oral solid dosage forms across Europe and beyond.
This article provides an exhaustive technical breakdown of , covering its scope, analytical requirements (disintegration, dissolution, uniformity), official interpretation, and common pitfalls in Quality Control (QC) laboratories.
Designed to change the rate, place, or time of drug release (e.g., prolonged or delayed release).